Health Care · Services-General Medical & Surgical Hospitals, NEC

HCA HCA Healthcare SEC Filings & Insider Trading Activity 2026

company
CIK 86073098 filings
S&P 500

HCA at a glance

HCA Healthcare (HCA, SEC CIK 860730) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), HCA Healthcare (HCA) reported revenue of $75.6 billion (up 7.1% from FY2024) and net income of $6.8 billion. Diluted EPS was $28.33.
  • As of September 30, 2026, 46 institutional investment managers tracked by SignalX reported holding HCA Healthcare (HCA) shares worth $20.3 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Rossitto Erica on November 10, 2026 of 3,500 shares at $505.81 per share.
  • In the last 90 days, HCA insiders reported 0 open-market purchases ($0) and 10 open-market sales ($18.3M) on Form 4, a net sale of $18.3M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$75.6B
+7.1% vs prior year
Insiders · 90 days
0 buys · 10 sells
Net −$18.3M
13F holders
46 funds
$20.3B · −4 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 1.01 · Item 2.03 · Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Operates healthcare facilities primarily through hospital services and affiliated outpatient centers
  • No new products, services, or segments introduced or emphasized in 2026 filing
  • Competitive positioning and strategy remain consistent with prior years; focus on governance and compliance highlighted
  • Equity compensation plans include 6.439 million securities issuable, weighted average exercise price $194.62, 27.913 million shares available for future issuance
  • Emphasis on enhanced governance disclosures and securities trading policy compliance, as detailed in proxy materials and investor relations website

Risk Factors

  • Indebtedness $46.5B as of 12/31/2025, risk of default if financial covenants under senior unsecured credit facility are breached
  • Workforce shortages and labor competition, including nurse-staffing ratio mandates in multiple states raising labor costs significantly
  • Cybersecurity risks from increased AI-driven attacks and state-sponsored threat actors targeting health data and operational systems
  • AI regulation risk: compliance with state laws California AB 3030, Utah AIPA, Colorado CAIA affecting generative AI use in patient care
  • Key management dependency risk: unexpected loss of senior managers could disrupt operations despite succession planning efforts

Management Discussion & Analysis

  • Operating cash flow $12.636B in 2025, up $2.122B from $10.514B in 2024 due to $1.319B net income increase and working capital improvements
  • Capital expenditures $4.944B in 2025, slightly up from $4.875B in 2024; acquisitions $397M in 2025 vs $266M in 2024
  • Financing cash use $8.550B in 2025 including $10.067B stock repurchases, $679M dividends; net debt increased $3.287B
  • Debt totaled $46.492B in 2025, up from $43.031B in 2024; interest expense $2.248B vs $2.061B with 5.0% average effective rate both years
  • Management expects 2026 capex $5.0B-$5.5B, sufficient liquidity from operations, $5.779B credit facility available, and access to debt markets

AI summary of the HCA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
  • Carried-forward risks incorporated by reference from the 2025 Form 10-K

Management Discussion & Analysis

  • Q3 revenue $19.849B, up 3.6% from $19.161B YoY
  • Net income margin 8.0% vs 8.6% YoY, income-before-tax margin 11.9% vs 12.6%
  • Best volume trend: emergency visits up 5.3% to 2,607,642; worst: outpatient surgeries down 4.2% to 242,819
  • Operating cash flow $4.461B, up $45M YoY; share repurchases $6.605B through nine months
  • Headwinds: uninsured admissions up 27.2%, EPTC expiration, administrative reforms, inflationary pressures and Medicaid policy changes; 2026 capex guidance $5.0B-$5.5B

AI summary of the HCA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • $6.5B senior note issuance, materially increasing HCA’s debt and future interest obligations
  • Fixed coupons range from 5.200% to 6.500%, with maturities spanning 2028 through 2056

Item 2.03: Creation of a Direct Financial Obligation

  • Item 2.03 links to Item 1.01 for details on a newly created direct financial obligation
  • Investors should review Item 1.01 for the obligation’s amount, terms, maturity and purpose

Item 8.01: Other Events

  • HCA entered an underwriting agreement on November 2, 2026 for the Issuer’s notes offering
  • Mizuho, Barclays, BofA Securities and Wells Fargo Securities serve as underwriter representatives
Filed Nov 2, 2026Full analysis →

Item 8.01: Other Events

  • HCA Inc. launched a proposed senior unsecured notes offering, signaling planned refinancing or debt-management activity
  • $1.200 billion of 4.500% senior notes due February 2027 targeted for redemption

Item EX-99.1: Item EX-99.1

  • Proposed senior-note offering by wholly owned HCA Inc. subsidiary, with size, maturity and interest rate pending pricing
  • Potential proceeds use: redeem $1.200 billion of 4.500% notes due February 2027
Filed Oct 27, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 30, 2026
  • Press release contains operating results and related financial details

Item 8.01: Other Events

  • Quarterly cash dividend declared at $0.78 per common share
  • Payment scheduled for December 29, 2026

Item 7.01: Regulation FD Disclosure

  • Third-quarter results for period ended September 30, 2026 announced October 27, 2026
  • Exhibit 99.1 contains operating results and accompanying management commentary

Item EX-99.1: Item EX-99.1

  • Q3 revenue rose 3.6% to $19.849B, while net income fell 3.9% to $1.579B
  • Uninsured volume from lost exchange coverage reduced pretax income by approximately $400M

AI summaries of HCA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for HCA

Don't miss the next HCA filing

  • Alerts as it files. A push when HCA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut HCA, by share count.
  • Ask anything. An AI agent that reads every HCA filing and answers with sources.

HCA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Schlosser Michael JGNov 13, 2026-
Schlosser Michael JGNov 13, 2026-
Rossitto EricaSellNov 10, 2026$505.81
Rossitto EricaMNov 6, 2026$101.16
Foster Jon MSellNov 6, 2026$498.00
Rossitto EricaMNov 6, 2026$81.96
Foster Jon MSellNov 6, 2026$493.58
Foster Jon MSellNov 6, 2026$498.97

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$65.0B$70.6B$75.6B
Net Income$5.2B$5.8B$6.8B
Net Margin8.1%8.2%9.0%
Balance Sheet
Total Assets$56.2B$59.5B$60.7B
Equity-$1.8B-$2.5B-$6.0B
ROE-295.5%-230.5%-112.6%
Per Share
EPS-$22.00$28.33
Cash Flow
Operating CF$9.4B$10.5B$12.6B
CapEx$4.7B$4.9B$4.9B

Source: XBRL data in HCA Healthcare (HCA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate HCA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
HCA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202646$20.34B
Q2 202650$20.18B
Q1 202647$26.63B
Q4 202548$26.16B
Q3 202552$25.69B
Q2 202549$23.35B
Q1 202546$16.56B
Q4 202443$11.48B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers

Source: 13F-HR filings on SEC EDGAR (aggregated from 381 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

HCA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 17, 2026--
4Nov 10, 2026--
4Nov 6, 2026--
4Nov 6, 2026--
4Nov 6, 2026--
4Nov 6, 2026--
8-KNov 5, 2026Analysis-
4Nov 3, 2026--
4Nov 2, 2026--
8-KNov 2, 2026Analysis-
10-QOct 29, 2026Analysis
8-KOct 27, 2026Analysis-
4Aug 28, 2026--
8-KJul 29, 2026Analysis-
10-QJul 28, 2026Analysis
8-KJul 24, 2026Analysis-
8-KJul 14, 2026Analysis-
8-KJun 18, 2026Analysis-
4May 11, 2026-
4Apr 30, 2026--
4Apr 30, 2026--
4Apr 30, 2026--
4Apr 30, 2026--
SC 13GApr 30, 2026-
8-KApr 30, 2026Analysis-

Related Health Care companies

All Health Care →

HCA SEC filings: frequently asked questions

Are HCA insiders buying or selling?

In the last 90 days, HCA Healthcare (HCA) officers, directors and 10% owners reported no open-market purchases and 10 open-market sales worth $18.3 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold HCA stock?

As of September 30, 2026, the largest HCA Healthcare (HCA) holders among the 13F filers tracked by SignalX were BlackRock ($5.3 billion), Vanguard Capital Management LLC ($4.0 billion), State Street Corp ($3.0 billion), Morgan Stanley ($1.1 billion), Vanguard Portfolio Management LLC ($1.1 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was HCA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), HCA Healthcare (HCA) reported revenue of $75.6 billion (up 7.1% from FY2024) and net income of $6.8 billion. Diluted EPS was $28.33. The figures come from the XBRL data in the 10-K.

What are the main risks in HCA's latest 10-K?

In the 10-K filed February 10, 2026, HCA Healthcare (HCA) flagged: Indebtedness $46.5B as of 12/31/2025, risk of default if financial covenants under senior unsecured credit facility are breached. Workforce shortages and labor competition, including nurse-staffing ratio mandates in multiple states raising labor costs significantly. (AI summary of the Risk Factors section.)

What did HCA report in its latest 8-K?

HCA Healthcare (HCA) filed an 8-K on November 5, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation) and Item 8.01 (Other Events). $6.5B senior note issuance, materially increasing HCA’s debt and future interest obligations.

What are the latest HCA SEC filings?

HCA Healthcare (HCA) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 17, 2026.

What is HCA's SEC CIK number?

HCA Healthcare (HCA)'s SEC Central Index Key (CIK) is 860730. EDGAR lists every HCA filing under that number.

Ask anything about HCA

The research agent reads HCA's filings, financials, insider trades and 13F holders, then answers with sources.